Six months supplementation with conjugated linoleic acid induces regional-specific fat mass decreases in overweight and obese
Six months supplementation with conjugated linoleic acid induces regional-specific fat mass decreases in overweight and obese
复制标题
DOI：
10.1017/s0007114507381324
复制
发表时间：
2007-03-01
影响因子：
3.6
通讯作者：
Gudmundsen, Ola
中科院分区：
文献类型：
--
作者：
Gaullier, Jean-Michel;Halse, Johan;Gudmundsen, Ola
长期补充共轭亚油酸（CLA）可以减少体脂量（BFM），增加或保持瘦体重（LBM）。然而，CLA的区域效应尚未研究。该研究旨在评估CLA在健康，超重和肥胖成年人中的作用和安全性。共有118名受试者（BMI：28-32 kg/m（2））被纳入一项双盲、安慰剂对照试验。受试者被随机分为两组，分别补充3.4 g/d CLA或安慰剂6个月。与安慰剂相比，CLA在第3个月（Delta =-0.9%，P = 0.016）和第6个月（Delta =-3.4%，P = 0.043）显著降低BFM。与安慰剂组相比，脂肪量的减少主要发生在腿部（Delta = -0-8 kg，P < 0.001）和BMI > 30 kg/m2（Delta =-1.9 kg，P = 0.011）的女性（Delta =-1.3 kg，P = 0.046）。与安慰剂相比，腰臀比显著降低（P = 0.043）。CLA组的LBM增加（Delta = +0.5 kg，P = 0.049）。骨矿物质含量未受影响（P = 0.70）。所有变化均与饮食和体育锻炼无关。包括血脂、炎症和致糖尿病标志物在内的安全性参数保持在正常范围内。两组之间的不良事件没有差异。得出的结论是，补充CLA在健康，超重和肥胖的成年人减少BFM在特定区域，是耐受性良好。
Long-term supplementation with conjugated linoleic acid (CLA) reduces body fat mass (BFM) and increases or maintains lean body mass (LBM). However, the regional effect of CLA was not studied. The study aimed to evaluate the effect of CLA per region and safety in healthy, overweight and obese adults. A total of 118 subjects (BMI: 28-32 kg/m(2)) were included in a double blind, placebo-controlled trial. Subjects were randomised into two groups supplemented with either 3.4 g/d CLA or placebo for 6 months. CLA significantly decreased BFM at month 3 (Delta = -0.9%, P = 0016) and at month 6 (Delta = -3.4%, P = 0043) compared with placebo. The reduction in fat mass was located mostly in the legs (Delta = -0-8 kg, P < 0.001), and in women (Delta = -1.3 kg, P = 0046) with BMI > 30 kg/m(2) (Delta = -1.9 kg, P = 0011), compared with placebo. The waist-hip ratio decreased significantly (P = 0043) compared with placebo. LBM increased (Delta = +0.5 kg, P = 0049) within the CLA group. Bone mineral content was not affected (P = 0.70). All changes were independent of diet and physical exercise. Safety parameters including blood lipids, inflammatory and diabetogenic markers remained within the normal range. Adverse events did not differ between the groups. It is concluded that supplementation with CLA in healthy, overweight and obese adults decreases BFM in specific regions and is well tolerated.